1. Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States


    Lisa M Hess et al, 2020, Pragmatic and Observational Research CrossRef
  2. Role of ARPC2 in Human Gastric Cancer
    Jun Zhang et al, 2017, Mediators of Inflammation CrossRef
  3. Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype
    Laura Caggiari et al, 2017, International Journal of Molecular Sciences CrossRef
  4. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type
    Chen Xu et al, 2017, Oncotarget CrossRef
  5. Conversion surgery after S-1 plus oxaliplatin combination chemotherapy for advanced gastric cancer with multiple liver metastases
    Tsutomu Namikawa et al, 2018, Clinical Journal of Gastroenterology CrossRef
  6. Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer
    Tsutomu Namikawa et al, 2018, Surgery Today CrossRef
  7. Role of general practice doctor in the treatment of Signet ring cell carcinoma
    Snežana Knežević et al, 2019, Praxis medica CrossRef
  8. Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer
    Giandomenico Roviello et al, 2018, Medicine CrossRef
  9. Review of survival, safety, and clinical outcomes in HER2+ metastatic gastric cancer following the administration of trastuzumabPost-Trastuzumab Gastric Cancer
    Michelle D. Hackshaw et al, 2020, Cancer Treatment and Research Communications CrossRef
  10. Clinical Implications of Molecular Heterogeneity of Gastric Cancer
    Petra Hudler et al, 2017, Gastric Cancer CrossRef
  11. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis
    A. Ilhan-Mutlu et al, 2018, Cancer Biology & Therapy CrossRef
  12. Structural basis of a novel heterodimeric Fc for bispecific antibody production
    Hudie Wei et al, 2017, Oncotarget CrossRef